Biohaven (BHVN) Return on Capital Employed (2022 - 2026)
Biohaven (BHVN) posted Return on Capital Employed of 160.81% for Q1 2026, up 32.18% sequentially from 237.12% in Q4 2025, and up 8677.0% YoY from 1.83% in Q1 2025.
Biohaven (BHVN) Return on Capital Employed (2022 - 2026) Analysis & Trends
Biohaven has reported Return on Capital Employed for 5 years, with the latest figure at 160.81% in Q1 2026.
- Quarterly Return on Capital Employed rose 8677.0% year-over-year to 160.81% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 160.81% (up 8677.0% YoY) and the FY2025 annual result came in at 178.6%, up 3731.0% from the prior year.
- Return on Capital Employed climbed to 160.81% in Q1 2026 per BHVN's latest filing, from 237.12% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 95.38% in Q2 2023 and troughed at 247.57% in Q1 2025.
- A 5-year average of 178.54% and a median of 197.33% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed tumbled 13148 bps in 2024, then jumped 8677 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 183.98% in 2022, then soared by 40 bps to 111.08% in 2023, then tumbled by 95 bps to 216.63% in 2024, then slipped by 9 bps to 237.12% in 2025, then jumped by 32 bps to 160.81% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 160.81%, 237.12%, and 216.11% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Biohaven | 2.21 Bn | 1.94 Bn | - | -159.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -159.43% |
| Mar 31, 2026 | -160.81% |
| Dec 31, 2025 | -237.12% |
| Sep 30, 2025 | -216.11% |
| Jun 30, 2025 | -210.69% |
| Mar 31, 2025 | -247.57% |
| Dec 31, 2024 | -216.63% |
| Sep 30, 2024 | -215.30% |
| Jun 30, 2024 | -226.86% |
| Mar 31, 2024 | -142.77% |
| Dec 31, 2023 | -111.08% |
| Sep 30, 2023 | -129.59% |
| Jun 30, 2023 | -95.38% |
| Mar 31, 2023 | -105.66% |
| Dec 31, 2022 | -183.98% |